+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 5 Actively Recruiting clinical trials

R

Actively Recruiting

Healthy Volunteer

Researchers are conducting a Phase 1 clinical trial to assess the safety, reactogenicity, and immune response of the YKYY025 injection, a respiratory syncytial virus RSV mRNA vaccine, in healthy adult participants. This randomized, double-blind, ascending-dose study involves both men and women aged 18 and older. The trial is sponsored by Beijing Youcare Kechuang Pharmaceutical Technology Co., Ltd. and aims to understand how the vaccine behaves in the body and its potential for preventing RSV infection. Participants will receive a single intramuscular injection of either the YKYY025 vaccine or a placebo in a randomized, parallel group design. The study includes ascending doses to evaluate the vaccines safety and immune response at different levels. The trial is structured with two parts based on age groups adults aged 18 to 49 years and those 50 years or older. During the study, participants will be monitored for adverse events up to 30 days post-vaccination and serious adverse events for up to 12 months. Heart activity will be assessed through 12-lead electrocardiograms within 4 days after vaccination. Immune responses will be measured by evaluating vaccine response rates and antigen-specific T cell levels at multiple time points up to 6 months after vaccination. Participants are expected to complete all study procedures and follow-up visits over the course of the trial.

Age: 18Years +All GendersPhase 1
1 location
A

Actively Recruiting

Researchers are conducting a prospective, multicenter, observational registry study to better understand treatment approaches, clinical practice changes, and cardiorenal risk outcomes in Chinese patients with chronic kidney disease CKD. This study aims to collect real-world data from about 3000 participants across various hospital types and geographic regions in China, reflecting diverse clinical care settings. Participants diagnosed with CKD will be enrolled and followed for up to 96 weeks. Data will be gathered at multiple sites including top-tier tertiary hospitals, regional medical centers, and secondary hospitals. Information will be collected from medical records and entered into a cloud-based electronic system to ensure quality and accuracy. The study does not involve administering treatments but observes existing clinical practices. During the study, investigators will monitor clinical indicators and outcomes related to CKD and associated conditions such as hypertension, heart failure, and hyperkalemia over the 96-week period. Medication use and changes in treatment strategies will be tracked. Participants will provide informed consent before enrollment and their health data will be regularly reviewed to assess long-term outcomes and treatment patterns.

All AgesAll Genders
59 locations
S

Actively Recruiting

Researchers are evaluating the effect of a triple therapy inhaler containing budesonide, glycopyrronium, and formoterol fumarate BGF MDI 32014.49.6 g compared to a dual therapy inhaler with glycopyrronium and formoterol fumarate GFF MDI 14.49.6 g on heart and lung outcomes in adults with chronic obstructive pulmonary disease COPD who have increased cardiopulmonary risk. This is a Phase III randomized, double-blind, parallel group, multi-center study designed to assess these treatments over an extended period. Participants will be randomly assigned to receive either the triple therapy BGF MDI or the dual therapy GFF MDI, each administered twice daily. The study aims to track the time to first severe cardiac or COPD event over up to three years. Both treatments involve pressurized inhalation suspensions delivered by metered-dose inhalers, and the study includes ongoing monitoring for up to three years during which various cardiopulmonary events and exacerbations will be recorded. During the study, participants will attend visits where their inhaler technique, lung function, blood markers such as eosinophil counts, and COPD assessment test scores will be evaluated. Researchers will measure outcomes including time to severe COPD exacerbations, cardiac events, cardiopulmonary death, and hospitalizations related to heart issues. Safety and efficacy will be closely monitored throughout the study duration, which may last up to three years, with regular follow-up assessments conducted in person or virtually as needed.

Age: 40Years - 80YearsAll GendersPhase 3
922 locations
L

Actively Recruiting

This research aims to study the long-term effects of successfully removing Pseudomonas aeruginosa PA infections in adults with bronchiectasis. It builds on a previous trial called ERASE that tested inhaled Tobramycin to clear PA in patients newly diagnosed with this infection. The goal is to see if eradicating PA improves health outcomes over a longer period. The study involves an extended observation period totaling 36 months, combining the first 9 months from the initial ERASE trial with an additional 27 months of follow-up. Participants are grouped based on whether they successfully cleared PA in the prior study. There is no new treatment given during this follow-up phase it is an observational study tracking patients over time. Participants will be monitored regularly for quality of life, lung function, frequency and severity of lung flare-ups, hospital visits, and treatment costs. Researchers will also check sputum samples at various time points up to 36 months to detect any return of PA infection. This comprehensive follow-up will help understand the long-term benefits and challenges after PA eradication in bronchiectasis patients.

Age: 18Years - 80YearsAll Genders
58 locations
S

Actively Recruiting

Researchers are evaluating benralizumab in patients aged 12 years and older with severe eosinophilic asthma to better understand its clinical profile and how well it works in a real-world setting in China. The study aims to observe early treatment responses, treatment outcomes, and changes in asthma control. It also looks at reasons why doctors may stop or switch benralizumab therapy. Participants receive benralizumab as prescribed by their clinician without any additional intervention from the study, as this is a non-interventional observational trial. The study collects data over time, focusing on asthma control and lung function. There is only one group of patients receiving benralizumab, and treatment decisions are made by healthcare providers as usual. Participants will be followed and monitored with asthma control questionnaires at weeks 1, 2, 4, 8, 16, 24, 40, and 56. Lung function changes will also be evaluated at weeks 8, 16, and 56. The primary outcome is asthma control at week 8. Data collection will continue until the study ends in January 2028, providing insights into treatment effects and patient experiences in routine care.

All AgesAll Genders
36 locations